Tremblay G, Biron P, Proulx A
Int J Clin Pharmacol Biopharm. 1978 Nov;16(11):508-12.
Twenty outpatients with mild angina were prescribed placebo tablets b.i.d. for 7 weeks followed by acebutolol, a cardioselective beta-blocker, 200 mg b.i.d. for 21 weeks under single-blind conditions. One graded multistage treadmill test was carried out after each treatment period and an angina diary was filled daily for the 6 months of the trial. Attack frequency declined by 71% from 2.59 per week on placebo to 0.76 per week on acebutolol (p less than 0.05). Exercise duration on the treadmill increased by 56%, from 5.95 minutes on placebo to 9.32 minutes on acebutolol (p less than 0.001). A satisfactory clinical response (50% or greater decline in attack frequency per week) occurred in 15 out of 19 patients (79%; a 100% or greater increase in exercise duration on the treadmill was observed in 10 out of 19 cases (53%). Exercise responsiveness was well predicted by exercise duration on placebo (r = 0.91, p less than 0.0005), patients with the least initial tolerance being the most improved. Clinical responsiveness was not well predicted by initial exercise tolerance (r = 0.38, N;S.) or by the improvement in exercise tolerance (r = 0.33, N.S.). It is concluded that acebutolol substantially reduces anginal attack frequency even in patients in whom exercise tolerance is not significantly improved, at the dose of 400 mg/day.
20名轻度心绞痛门诊患者被给予安慰剂片，每日两次，持续7周，随后在单盲条件下给予心脏选择性β受体阻滞剂醋丁洛尔，每日两次，每次200mg，持续21周。在每个治疗期后进行一次分级多级平板运动试验，并在试验的6个月内每天填写心绞痛日记。发作频率从安慰剂组的每周2.59次下降71%至醋丁洛尔组的每周0.76次（p<0.05）。平板运动的持续时间增加了56%，从安慰剂组的5.95分钟增至醋丁洛尔组的9.32分钟（p<0.001）。19名患者中有15名（79%）出现了满意的临床反应（每周发作频率下降50%或更多）；19例中有10例（53%）观察到平板运动持续时间增加100%或更多。运动反应性可通过安慰剂组的运动持续时间得到很好的预测（r = 0.91，p<0.0005），初始耐受性最差的患者改善最为明显。初始运动耐受性（r = 0.38，无显著性差异）或运动耐受性的改善（r = 0.33，无显著性差异）均不能很好地预测临床反应性。得出结论：即使在运动耐受性没有显著改善的患者中，醋丁洛尔以400mg/天的剂量也能显著降低心绞痛发作频率。
